Buy Rimonabant Acomplia Pills Online
Monday, January 28th, 2008News About Rimonabant Acomplia Drug
Acomplia (rimonabant) is really a wonder with so many controversies and point of admirations, which bred a strong curiosity regarding the drug. You can buy acomplia for weight loss, but it is not yet approved for smoking cessation as it is under observation of FDA. So buy acomplia and it will help you lose weight. Being the developer of the drug the Paris based concern Sanofi-Aventis was seen to show a high degree of boastful confidence for the future prospect of Acomplia as a diet drug or the weight loss pill in the 27th Conference Annual Goldman Sachs Global Healthcare, in Dana Point in California. Although this creation of Sanofi-Aventis has not been approved as the smoking cessation drug, the key Committee of European Medicines Agency (EMEA) has recommended approval of the Acomplia (rimonabant) as an aid to weight loss. aid to weight loss. How acomplia works is very simple. It just suppresses the patient’s appetite, affecting the endocannsbinoid system which gets highly stimulated due to overeating. By this patients are restrained from over eating, leading to successful weight loss and thereby combating obesity. As far as smoking cessation process is concerned, Acomplia is yet to get approval for the same.Generic version of Diet Pill Rimonabant can now be purchased by patients who obtain a prescription from a general practitioner. The miraculous multifunctional pill helps you short out obesity as well as smoking. Generic Acomplia (Rimonabant) diet pills work on the Endocannabinoid system, which controls appetite and energy expenditure (as well as the urge to smoke). This wonder pill selectively blocks some receptors in the Endocannabinoid system, thus creating a better balance which in turn suppresses appetite and the longing to overeat [buy rimonabant].
Additional Benefits of Generic Acomplia (Rimonabant)
Generic Acomplia (Rimonabant) is not only beneficial for obese people but it is also a dream come true for those who wish to quit smoking. Although primarily it is for obese people, still it’s usefulness for the smoking cessation also. This dual nature of drug adds to its USP. Also, in the earlier trials, it has been confirmed that it is an effective way to relinquish smoking.Sanofi Aventis launches its weight loss drug Acomplia today in the UK. The once-a-day pill was shown to help 40 percent of obese participants lose 10 percent of their body weight in clinical trials.Acomplia works to control appetite by blocking brain activity that regulates the body’s energy and its ability to break down fats and sugars in the blood. The drug was found to reduce disease-causing fatty deposits around internal organs.However, the supposed “blockbuster” drug also comes with side effects, including dizziness, nausea, anxiety, diarrhea and insomnia.Acomplia — commonly known as rimonabant — will be made available in the UK to obese patients with a body mass index (BMI) of 30 or more, and to overweight patients with a BMI of 27 or more who either lack “good” HDL cholesterol, have too much “bad” LDL cholesterol, or are at risk of developing type 2 diabetes. Rimonabant will only be available to those patients who also commit to making healthy dietary and exercise changes [buy acomplia].
Critics of the drug say diet and exercise — without prescription drugs — should be enough to help people lose weight, especially considering that Acomplia comes with potentially harmful side effects. Many natural alternatives exist that control cravings and reduce appetite without the use of expensive and potentially dangerous prescription drugs.
A report in The Lancet is stirring heightened interest in the new weight-loss drug Acomplia (rimonabant), expected to be available in the U.S. next year. The report was based on one-year results from the RIO-Europe clinical trial, which showed that Acomplia could substantially reduce the weight, waist circumference and risk factors for heart disease in obese people.Acomplia has been hailed by some doctors on the basis of interim study results as potentially a major breakthrough in treating obesity, according to the Acomplia Report, a Web newsletter.Other once-promising anti-obesity drugs like Xenical, Meridia (Reductil in Europe), and phentermine, however, have proven to have troublesome side effects, disappointing millions of dieters, the report noted.Another diet drug under development, Axokine, also has been reported to have a high rate of side effects in clinical trials.In the Lancet article, Dr. Luc Van Gaal of University Hospital in Antwerp, Belgium, the lead researcher in the RIO-Europe trial, said treatment with the drug over one year led to “sustained, clinically meaningful weight loss, reduction in waist circumference [buy rimonabant acomplia], and associated improvements in several cardiovascular and metabolic risk factors.”In an accompanying editorial, Drs. Uberto Pagotto and Renato Pasquali of Sant Orsola-Malpighi General Hospital, Bologna, Italy, support the assertion, writing: “A new pharmacological treatment to tackle obesity, and alterations of metabolic and lipid profiles that are often associated, could now be close to clinical practice.”"These data, and those from the other ongoing clinical trials with rimonabant, might presumably help us to better tackle obesity and related metabolic and cardiovascular disease.”

